首页> 外文期刊>Pathology oncology research: POR >Immunocytochemistry Based on a Cell-Type-Specific Aptamer for Rapid Immunostaining of Adenocarcinoma Cells in Clinical Serosal Fluids
【24h】

Immunocytochemistry Based on a Cell-Type-Specific Aptamer for Rapid Immunostaining of Adenocarcinoma Cells in Clinical Serosal Fluids

机译:基于细胞型特异性适体的免疫细胞化学,用于在临床浆液中快速免疫腺癌细胞的快速免疫染色

获取原文
           

摘要

All too often, conventional immunocytochemistry (ICC) via an antibody on cytological samples is limited to a few smears due to scant cellularity. To circumvent these limitations, this study employed a cell-type-specific aptamer as the core tool in ICC protocols for a timely and highly specific ICC diagnosis. S6, an aptamer against A549 lung carcinoma cells, was adopted instead of antibodies in this study for differentiating cancer cells in serosal fluids. Here, we developed three different strategies for discriminating the adenocarcinoma cells in effusion cytology specimens using the S6 aptamer in ICC. These strategies included a biotin-labeled S6 aptamer, an FAM-labeled S6 aptamer, and an activatable S6 aptamer. A total of 112 serosal fluid specimens with known diagnoses were evaluated by all three modes of use of the S6 aptamer. ICC procedures based on biotin-labeled or FAM-labeled S6 aptamers required time-consuming washing to avoid interference from nonspecific adsorption. ICC procedures based on an activatable S6 aptamer probe showed a weak fluorescence signal in the absence of target cells, but the procedures showed a strong fluorescence signal due to alteration of the conformation without any complicated washing steps, in the presence of targets. The specificity and sensitivity are higher in all three different ICC protocols based on the S6 aptamer than those for antibody protocols for differentiating adenocarcinoma cells in clinical effusion cytology. ICC based on cell-type-specific aptamers, instead of on a panel of a set of antibodies, is promising as an auxiliary method for the diagnosis of cancer.
机译:通常,通过抗体在细胞学样品上通过抗体的常规免疫细胞化学(ICC)限制为少量涂片引起的味道。为了规避这些限制,本研究采用细胞型特异性适体作为ICC协议中的核心工具,用于及时和高度特异性的ICC诊断。 S6,采用针对A549肺癌细胞的适体,而不是本研究中的抗体,用于区分浆液中的癌细胞。在此,我们使用ICC中的S6适体鉴别识别血液化细胞学样本中的腺癌细胞的三种不同的策略。这些策略包括生物素标记的S6适体,FAM标记的S6适体和可激活的S6适体。通过S6适体的所有使用方式评估总共112个具有已知诊断的血清体液样本。 ICC程序基于生物素标记或FAM标记的S6适体需要耗时的洗涤,以避免非特异性吸附的干扰。基于可激活的S6适体探针的ICC程序在不存在靶细胞的情况下显示出弱荧光信号,但由于在靶标存在下,由于构象的改变而没有任何复杂的洗涤步骤,该方法显示出强烈的荧光信号。基于S6适体的所有三种不同ICC协议的特异性和敏感性高于抗体方案,用于区分临床积分细胞学中的抗体方案。基于细胞型特异性适体的ICC,而不是在一组抗体的面板上,是作为诊断癌症的辅助方法。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号